HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 89.9%

Neg 0% Neu 89.9% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Buy and maintains $20 price target.